Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Assets (2022 - 2026)

HeartSciences filings provide 5 years of Assets readings, the most recent being $7.6 million for Q1 2026.

  • On a quarterly basis, Assets rose 32.45% to $7.6 million in Q1 2026 year-over-year; TTM through Jan 2026 was $7.6 million, a 32.45% increase, with the full-year FY2025 number at $4.2 million, down 55.56% from a year prior.
  • Assets hit $7.6 million in Q1 2026 for HeartSciences, up from $6.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $10.8 million in Q1 2024 to a low of $2.1 million in Q2 2022.
  • Median Assets over the past 5 years was $5.6 million (2022), compared with a mean of $5.6 million.
  • Biggest five-year swings in Assets: surged 228.38% in 2024 and later plummeted 55.56% in 2025.
  • HeartSciences' Assets stood at $4.8 million in 2022, then plummeted by 50.36% to $2.4 million in 2023, then surged by 228.38% to $7.8 million in 2024, then decreased by 22.9% to $6.0 million in 2025, then grew by 25.99% to $7.6 million in 2026.
  • The last three reported values for Assets were $7.6 million (Q1 2026), $6.0 million (Q4 2025), and $6.4 million (Q3 2025) per Business Quant data.